Laninamivir Octanoate

Summary

Laninamivir Octanoate (CHEMBL467058) is an approved small molecule; indicated across 2 conditions including influenza and asthma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 472.5 Da · C21H36N4O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL467058
Name	Laninamivir Octanoate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9847629
Molecular formula	C21H36N4O8
Molecular weight	472.5
InChIKey	UKTIJASCFRNWCB-RMIBSVFLSA-N

SMILES: CCCCCCCC(=O)OC[C@H]([C@H]([C@H]1[C@@H]([C@H](C=C(O1)C(=O)O)N=C(N)N)NC(=O)C)OC)O

IUPAC name: (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2-hydroxy-1-methoxy-3-octanoyloxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid

Also known as: Cs-8958, Laninamivir octanoate, Laninamivir octanoic acid ester, R-118958, laninamivir octanoate, LANINAMIVIR OCTANOATE, Laninamivir-F4 octanoate, Laninamivir octanoate; Inavir

Parent form; salt/anhydrous children: CHEMBL2093880

Patent coverage: 172 distinct patent families (437 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 327 (75%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
influenza	3	MONDO:0005812	EFO:0007328
asthma	1	MONDO:0004979	MONDO:0004979

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	2
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00803595	PHASE3	COMPLETED	A Multinational Phase III Study of CS-8958 (MARVEL)
NCT01793883	PHASE2	COMPLETED	Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza
NCT02014649	PHASE1/PHASE2	TERMINATED	Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza
NCT00995826	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958
NCT02022761	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).